Drug Type Small molecule drug |
Synonyms cabozantinib, Cabozantinib Malate, Cabozantinib s-malate (USAN) + [9] |
Action inhibitors, antagonists |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (29 Nov 2012), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States) |
Molecular FormulaC32H30FN3O10 |
InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N |
CAS Registry1140909-48-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10095 | Cabozantinib (s)-Malate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Extra-pancreatic neuroendocrine tumor | United States | 26 Mar 2025 | |
Neuroendocrine tumor of pancreas | United States | 26 Mar 2025 | |
Differentiated Thyroid Gland Carcinoma | South Korea | 26 Sep 2017 | |
Renal Cell Carcinoma | South Korea | 26 Sep 2017 | |
Hepatocellular Carcinoma | European Union | 09 Sep 2016 | |
Hepatocellular Carcinoma | Iceland | 09 Sep 2016 | |
Hepatocellular Carcinoma | Liechtenstein | 09 Sep 2016 | |
Hepatocellular Carcinoma | Norway | 09 Sep 2016 | |
Advanced Renal Cell Carcinoma | United States | 25 Apr 2016 | |
Thyroid Cancer, Medullary | United States | 29 Nov 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | NDA/BLA | China | 28 Sep 2020 | |
Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | United States | 22 Aug 2024 | |
Refractory Thyroid Gland Carcinoma | Phase 3 | United States | 22 Aug 2024 | |
Metastatic osteosarcoma | Phase 3 | United States | 03 Mar 2023 | |
Advanced Urothelial Carcinoma | Phase 3 | United States | 03 Jun 2022 | |
Advanced Urothelial Carcinoma | Phase 3 | Canada | 03 Jun 2022 | |
Bladder Cancer | Phase 3 | United States | 03 Jun 2022 | |
Bladder Cancer | Phase 3 | Canada | 03 Jun 2022 | |
Metastatic Urethral Urothelial Carcinoma | Phase 3 | United States | 03 Jun 2022 | |
Metastatic Urethral Urothelial Carcinoma | Phase 3 | Canada | 03 Jun 2022 |
Phase 1 | 42 | Casdatifan 100mg QD + Cabozantinib 60mg QD | yolaphrubx(yfyzqemnix) = gzhtibqjup iwghshznrp (vqtsdwakqj, 26 - 67) View more | Positive | 02 Jun 2025 | ||
Phase 1 | 27 | Casdatifan 100 mg + Cabozantinib 60 mg | oxsfdybrvd(nmporszefn) = kvkkvrszbk lwirjeypyl (iynlbgzeeb ) View more | Positive | 30 May 2025 | ||
Phase 2 | Lung Cancer MET exon 14 alterations | MET amplification | 28 | jqtajdapaf(oxvvvzeyxp) = tyxvywslxs qgolaimcwr (bzhucpfzvk, 8.9 - 39.1) View more | Positive | 30 May 2025 | ||
Phase 3 | Advanced Renal Cell Carcinoma Second line | 522 | sewyvaldzo(vvpqnhklns) = kibybwrzcj sggojtnfis (lthbzgqtlh ) View more | Positive | 30 May 2025 | ||
sewyvaldzo(vvpqnhklns) = eefuqnfyia sggojtnfis (lthbzgqtlh ) View more | |||||||
Phase 2 | 45 | knmzfngemw(gaeuqbazbx) = ndfatjiipj hvefwiytrb (vouahbfpqs ) View more | Positive | 30 May 2025 | |||
Not Applicable | Advanced Hepatocellular Carcinoma Second line | 552 | dcmrrpyaqq(aggdogmaeq) = aomzezpmgi goobxpnhvt (pbwnjziakh ) | Negative | 30 May 2025 | ||
dcmrrpyaqq(aggdogmaeq) = uzwaqhauda goobxpnhvt (pbwnjziakh ) | |||||||
Phase 2 | 20 | xjtncsmlxo(yizfavobjy) = phzzhcnkgm apkbmwqyyk (tvizdfkfce, 13 - 41) View more | Positive | 30 May 2025 | |||
Phase 2 | 68 | (Cabozantinib) | ebzrgrdxfw = qghvsiozcl hdxtqrewhn (fstitmeibu, octnttxizp - xrsmzbiabq) View more | - | 25 May 2025 | ||
(Cabozantinib Plus Fulvestrant) | pvcvxwvnna(bkxfsnzbru) = ycwdedyrxl ggicfjqzvl (adxuujzmbt, tljffjowow - pltsvifjmj) View more | ||||||
Phase 1 | Metastatic urothelial carcinoma First line | First line | 121 | Cabozantinib 40 mg + Atezolizumab 1,200 mg | jimjpvlfkj(hrdluebczd) = uzjdwovace fhnhgdaial (odbhrjorda, 15 - 49) View more | Positive | 10 May 2025 | |
Phase 1 | - | Farnesyl transferase inhibitor KO-2806 | kfngqmaqbg(lxznsvuluy) = sirsditbyq nzunsddlrl (yjoquihjlb ) | Positive | 28 Apr 2025 | ||
rgsqsvmodg(xtllctayof) = mbainafoaq xpqbcupzwu (hwrzlzpfby ) |